Details
Stereochemistry | ACHIRAL |
Molecular Formula | C19H20N6O |
Molecular Weight | 348.4017 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O=C(NC1=CC=CC(=C1)C2=NCCN2)NC3=CC=CC(=C3)C4=NCCN4
InChI
InChIKey=SCEVFJUWLLRELN-UHFFFAOYSA-N
InChI=1S/C19H20N6O/c26-19(24-15-5-1-3-13(11-15)17-20-7-8-21-17)25-16-6-2-4-14(12-16)18-22-9-10-23-18/h1-6,11-12H,7-10H2,(H,20,21)(H,22,23)(H2,24,25,26)
Imidocarb is a carbanilide derivative with antiprotozoal activity. It is usually administered as the dipropionate salt. Imidocarb is a drug sold under the brand name Imizol and is used to treat canine ehrlichiosis. wo mechanisms of action have been proposed:
As the effect of imidocarb on Trypanosoma brucei is antagonized by excess polyamines, it is has been suggested that imidocarb interferes with their production and/or use. Imidocarb blocks the entry of inositol into erythrocytes containing Babesia, resulting in starvation of the parasite. It is generally accepted in that imidocarb has anticholinesterase activity.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL4768 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27301742 |
|||
Target ID: CHEMBL2966 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27301742 |
|||
Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20053484 |
590.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Imizol Approved UseFor the treatment of babesiosis in dogs with clinical signs and/or demonstrated Babesia organisms in the blood. Launch Date1997 |
|||
Curative | IMIDOCARB Approved UseFor treatment of babesiosis in cattle and horses Launch Date2001 |
PubMed
Title | Date | PubMed |
---|---|---|
Cationic antitrypanosomal and other antimicrobial agents in the therapy of experimental Pneumocystis carinii pneumonia. | 1988 Jun |
|
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
Residual effect of antibabesial drugs on the live redwater blood vaccines. | 2002 Oct |
|
Effects of imidocarb dipropionate in cats with chronic haemobartonellosis. | 2002 Summer |
|
Evaluation of certain veterinary drug residues in food. | 2003 |
|
Naturally acquired babesiosis in a reindeer (Rangifer tarandus tarandus) herd in Great Britain. | 2003 Feb |
|
Humoral immunity and reinfection resistance in dogs experimentally inoculated with Babesia canis and either treated or untreated with imidocarb dipropionate. | 2003 Jun 25 |
|
In-vivo therapeutic efficacy trial with artemisinin derivative, buparvaquone and imidocarb dipropionate against Babesia equi infection in donkeys. | 2003 Nov |
|
Concurrent bartonellosis and babesiosis in a dog with persistent thrombocytopenia. | 2003 Nov 1 |
|
Imidocarb, a potent anti-protozoan drug, up-regulates interleukin-10 production by murine macrophages. | 2003 Sep 19 |
|
[Autochthonous babesiosis in dogs in the Netherlands?]. | 2004 May 1 |
|
Detection and molecular characterization of a novel large Babesia species in a dog. | 2004 Oct 5 |
|
Autochthonous canine babesiosis in The Netherlands. | 2005 Jul 15 |
|
Clinical and clinicopathological changes in 6 healthy ponies following intramuscular administration of multiple doses of imidocarb dipropionate. | 2005 Mar |
|
Pharmacokinetics and mammary elimination of imidocarb in sheep and goats. | 2006 Jul |
|
Flow cytometric evaluation of selected antimicrobial efficacy for clearance of Anaplasma marginale in short-term erythrocyte cultures. | 2006 Jun |
|
Effect of imidocarb and levamisole on the experimental infection of BALB/c mice by Leishmania (Leishmania) amazonensis. | 2006 Jun 30 |
|
Clinicopathological changes and effect of imidocarb therapy in dogs experimentally infected with Babesia canis. | 2006 Mar |
|
Comparison of the efficacy of enrofloxacin, imidocarb, and oxytetracycline for clearance of persistent Anaplasma marginale infections in cattle. | 2006 Winter |
|
Pharmacokinetics and bioavailability of imidocarb dipropionate in swine. | 2007 Aug |
|
Histological and ultrastructural studies of renal lesions in Babesia canis infected dogs treated with imidocarb. | 2007 Dec |
|
Evidence of an acute phase response in dogs naturally infected with Babesia canis. | 2007 Mar 31 |
|
Therapeutic and prophylactic efficacy of imidocarb dipropionate on experimental Babesia ovis infection of lambs. | 2007 Oct 21 |
|
[Dogs babesiosis--still actually problem]. | 2008 |
|
Canine vector-borne diseases in Brazil. | 2008 Aug 8 |
|
Treatment of Mycoplasma wenyonii infection in cows with imidocarb dipropionate injection-acupuncture. | 2008 Dec |
|
Repeated high dose imidocarb dipropionate treatment did not eliminate Babesia caballi from naturally infected horses as determined by PCR-reverse line blot hybridization. | 2008 Feb 14 |
|
Ultrastructural and fluorochromatic changes of Anaplasma marginale exposed to oxytetracycline, imidocarb and enrofloxacin in short-term erythrocyte cultures. | 2009 Apr 14 |
|
Alterations in some blood coagulation parameters in naturally occurring cases of canine babesiosis. | 2009 Jun |
|
Diagnosis and treatment of Babesia odocoilei in captive reindeer (Rangifer tarandus tarandus) and recognition of three novel host species. | 2009 Mar |
|
Babesia and its hosts: adaptation to long-lasting interactions as a way to achieve efficient transmission. | 2009 Mar-Apr |
|
Detection of a large unnamed Babesia piroplasm originally identified in dogs in North Carolina in a dog with no history of travel to that state. | 2009 Oct 1 |
|
Haemotropic mycoplasmas: what's their real significance in cats? | 2010 May |
|
Detection of Babesia divergens in southern Norway by using an immunofluorescence antibody test in cow sera. | 2010 Oct 6 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/vet/imizol.html
Use intramuscularly or subcutaneously at a rate of 6.6 mg/kg (3 mg/lb) body weight. Repeat the dose in two (2) weeks, for a total of two (2) treatments.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2242963
The concentration of Imidocarb causing 50% inhibition of [3H]hypoxanthine incorporation (ID50 value) by Babesia bovis (Lismore and Samford isolates) cultured in vitro for Imidocarb was determined to be 3 ng/ml (8.6 nM).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C277
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
||
|
WHO-VATC |
QP51AE01
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB08146MIG
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
IMIDOCARB
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
D007095
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
8USS3K0VDH
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
C83790
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
1740237
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
DB11521
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
DTXSID0048345
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
8USS3K0VDH
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
m6226
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | Merck Index | ||
|
248-711-7
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
100000083918
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
21389
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
51804
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
27885-92-3
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
2906
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY | |||
|
CHEMBL427342
Created by
admin on Fri Dec 15 17:24:42 GMT 2023 , Edited by admin on Fri Dec 15 17:24:42 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)
SALT/SOLVATE (PARENT)